Browsing Tag
Bristol Myers Squibb
36 posts
Bristol Myers Squibb (NYSE: BMY) expands Opdivo into frontline Hodgkin lymphoma, strengthening immuno-oncology leadership
Bristol Myers Squibb expands Opdivo in Hodgkin lymphoma. Discover how this reshapes treatment strategy, competition, and long-term oncology trends.
What continuous drug exposure could mean for immunomodulatory therapy in multiple myeloma
Can continuous lenalidomide exposure reshape immunomodulatory therapy economics? Explore the strategic stakes for Starton Therapeutics Inc.
Is Orencia finally vulnerable? Dr. Reddy’s abatacept biosimilar clears a key FDA hurdle
Dr. Reddy’s abatacept biosimilar enters FDA review. See what this means for Orencia, biosimilar policy, and U.S. autoimmune drug pricing.
FDA approves Cytokinetics’ MYQORZO for obstructive HCM after SEQUOIA-HCM trial success
FDA approves Cytokinetics’ aficamten for obstructive HCM. Find out what this means for cardiologists, patients, and rival Camzyos as MYQORZO prepares to launch.
Why Bristol Myers Squibb is giving away Eliquis to Medicaid and what it signals for U.S. drug pricing next
Bristol Myers Squibb will offer Eliquis free to Medicaid under a U.S. pricing deal. Find out what it means for drug pricing, investors, and patients.
Accenture (NYSE: ACN) posts strong Q1 FY2026 earnings, but exits AI metric reporting as enterprise integration takes hold
Accenture beats Q1 FY26 estimates and retires AI reporting, signaling deep enterprise integration. Find out what it means for clients and investors.
Bristol Myers Squibb signs $1.1bn multi-specific antibody discovery deal with Harbour BioMed
Harbour BioMed signed a $1.125B discovery deal with Bristol Myers Squibb to co-develop multi-specific antibodies. Read the full strategic breakdown now.
Milvexian setback: Phase 3 Librexia ACS trial discontinued as interim data shows futility for Bristol Myers Squibb and Johnson & Johnson
Find out how the Librexia ACS trial discontinuation reshapes the future of milvexian and what it means for cardiovascular drug development today.
The next frontier: Can CAR T therapy become a one-time cure for autoimmune diseases?
Can CAR T therapy move beyond cancer and offer one-time remission for autoimmune disease? A deep look at early data, industry shifts, and clinical implications.
MapLight Therapeutics prices $250m Nasdaq IPO at $17 a share as biotech listings rebound
Find out how MapLight Therapeutics’ $250 million Nasdaq IPO is reigniting biotech investor sentiment and funding its next wave of CNS drug trials.